Investor Relations

Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$14.75 - 0.25
Stock chart for: ZGNX.O.  Currently trading at $14.75 with a 52 week high of $15.40 and a 52 week low of $7.33.
Data as of 06/26/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix June 2017 Investor Presentation
Download Documentation

Recent News More

Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome

Read More

Zogenix to Present at the Jefferies 2017 Global Healthcare Conference

Read More